Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.34 |
| ▸ | CHRNA10 | Q9GZZ6 | 6/20 | 0.34 |
| ▸ | CHRNA9 | Q9UGM1 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737196 | 0.85 | KDM4E (0.51) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| SCHEMBL28333949 | 0.79 | LMNA (0.60) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| SCHEMBL5953790 | 0.78 | LMNA (0.48) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| Bromide SCHEMBL10428847 | 0.78 | LMNA (0.58) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| SCHEMBL20524228 | 0.74 | TERT (0.46) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| SCHEMBL20524229 | 0.72 | TERT (0.47) | APOBEC3AAPOBEC3GLMNAL3MBTL1CYP1A2 | |
| SCHEMBL29556923 | 0.70 | — | — | |
| SCHEMBL294294 | 0.70 | — | — | |
| SCHEMBL9091930 | 0.70 | KDM4E (0.44) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA | |
| SCHEMBL5286663 | 0.69 | APOBEC3A (0.36) | KDM4EPKMAPOBEC3AAPOBEC3GLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018183749-A1 | TRIAZINIUM CATION FORMS AND METHODS OF MAKING THEREOF | LOYOLA UNIVERSITY NEW ORLEANS (US) | 2018-10-04 | — | — | WO | claimed |
| US-10961224-B2 | Triazinium cation forms and methods of making thereof | LOYOLA UNIVERSITY NEW ORLEANS (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2018183749-A1 | TRIAZINIUM CATION FORMS AND METHODS OF MAKING THEREOF | LOYOLA UNIVERSITY NEW ORLEANS (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961224-B2 | Triazinium cation forms and methods of making thereof | MITF, SOD1, TYR | KDM4E 2914/4885PKM 2069/4885APOBEC3A 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.